December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
29 citations
,
July 1996 in “Acta Paediatrica” Biotin should be added to Japanese amino acid formula to prevent deficiency.
January 2026 in “Journal of Aesthetic Medicine” Aesthetic care should align physical changes with mental well-being using a comprehensive, multidisciplinary approach.
18 citations
,
October 2022 in “JCI Insight” Abnormal amino acid metabolism may worsen rosacea symptoms.
January 2013 in “Frontiers in Immunology” Parental uveitis increases offspring's risk and severity of autoimmune eye disease.
5 citations
,
September 2013 in “The Journal of Dermatology” Researchers found a new mutation in the HR gene causing hair loss and skin bumps in a Pakistani family.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
6 citations
,
January 2000 in “The Journal of Trace Elements in Experimental Medicine” Zinc supplements effectively treat acrodermatitis enteropathica.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
67 citations
,
March 2021 in “Dermatology and Therapy” Alopecia areata greatly harms quality of life, causing emotional and social issues.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
Hair loss significantly lowers life quality, especially in young men, with most patients unhappy with treatment effectiveness.
6 citations
,
October 2016 in “Pediatric Dermatology” A 6-year-old girl had a rare allergic reaction to a hair regrowth treatment.
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
June 2016 in “The Egyptian Journal of Forensic Sciences and Applied Toxicology” Long-term exposure to benzene increases skin diseases, blood disorders, and liver problems.
3 citations
,
March 2012 in “Journal of the Egyptian Public Health Association /Journal of the Egyptian Public Health Association” General practitioners in Qassim have satisfactory knowledge of alopecia areata but need more education to address gaps and misconceptions.
Baricitinib shows promise for treating alopecia areata with mild side effects.
October 2023 in “Journal of Family Medicine and Primary Care” More awareness and education on iron deficiency anemia are needed in Riyadh.